- 1997
- Development of artificial base pair technology begins.
- 2006
- Ds Artificial base technology development
- 2007
- Established TAGCyx Biotechnologies Inc.
- 2009
- Development of Ds-Px base pair technology Detail
- 2015
- Aptamer stabilization technology
- 2016
- Next generation aptamer stabilization technology
- 2016
- Business focus change to drug development
- 2017
- Moved from RIKEN Yokohama Campus to The University of Tokyo
- 2018
- Collaborative research agreement with HEALIOS K.K.
- 2019
- Collaborative research agreement with Chiome Bioscience Inc.
- 2019
- Collaborative research agreement with GlyTech, Inc.
- 2020
- Collaborative research and development agreement with GC Pharma
- 2020
- Collaborative research collaboration with CAGE Bio Inc
- 2020
- Commissioned Development Agreement with Showa Denko Materials
- 2020
- Research and development collaboration with SBI Pharmaceuticals
- 2021
- Worldwide exclusive supply of Ds amidite and patent license agreement with Otsuka Chemical Co., Ltd.
- 2021
- Development of new artificial base pairing technology
- 2022
- License agreement for development and commercialization of TAGX-0003 for the treatment of immunodermatology diseases with CAGE Bio Inc.
